Male fertility testing is a growing $21.7B market, with rising demand from IVF centers and fertility clinics worldwide. However, traditional testing systems are expensive, complex, and confined to specialized laboratories, limiting market access and scalability.
Large-scale studies have established sperm quality as a validated biomarker for overall male health and longevity, opening additional market opportunities in preventive health screening and longevity medicine.
YScope addresses both markets through an innovative portable microscopy platform. At a fraction of the cost of traditional systems, our computer-aided sperm analysis (CASA) technology delivers laboratory-grade fertility diagnostics in any clinical setting, while enabling broader health assessment applications. Combined with smart consumables and digital health integration, YScope creates multiple revenue streams across fertility, health screening, and longevity markets.
Protected by patents through 2038 and validated through 10,000+ veterinary analyses, YScope is now available for exclusive human medical market expansion.
Contact Dr. Tamas Babel to access the complete due diligence package and discuss acquisition terms.